Why the study?
The safety and efficacy of the novel selective cardiac myosin activator omecamtiv mecarbil is being tested in HFrEF, prompting description and comparison of GALACTIC-HF participant baseline characteristics with other contemporary trials.
Key points are not available for this paper at this time.
Population
8256 adults with established HFrEF, NYHA class ≥II, EF ≤35%, and elevated natriuretic peptides
Comparison
Omecamtiv mecarbil (pharmacokinetic-guided dosing: 25, 37.5, or 50 mg bid) vs placebo
Design
Randomized controlled trial baseline characteristic description
No takes yet. Share an insight, caveat, or question.
Provides GALACTIC-HF baseline profile for context; leaves open generalizability to broader HFrEF populations.
Teerlink et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: